AbbVie Inc. (ABBV)
Aging Population Drives Healthcare Growth: Stocks to Watch
AbbVie, Tandem Diabetes Care and Amgen are targeting aging-related healthcare growth through advances in immunology, diabetes and cardiovascular care.
AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie continues to expand its immunology and neuroscience portfolio through strategic acquisitions. Eli Lilly and is seeing massive revenue growth driven by high demand for its metabolic therapies.
AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease
ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.
3 Dividend Stocks, 12 Paychecks a Year: How to Get Paid Every Month
Building a monthly income stream from quarterly dividend payers requires just a little scheduling. Three blue chips, staggered on different quarterly calendars, can deliver a paycheck in every month of the year.
When Inflation Is Sticky, 5 Dividend Aristocrats Are the Stocks to Own Now and Forever
Sticky inflation is quietly rewarding a specific group of stocks with decades of uninterrupted dividend growth, and Wall Street's top analysts say five of them are built to profit no matter how long rising prices persist.
How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?
AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.
AbbVie Still Has Room To Run
AbbVie continues to deliver robust top-line and EPS growth, with Skyrizi and Rinvoq strength offsetting Humira declines. Skyrizi and Rinvoq drive growth. Recent regulatory approvals and expanded market potential support AbbVie's long-term positioning. Despite a forward P/E expansion to 18.89, AbbVie trades at a discount to the sector, with a non-GAAP forward PEG of 1.40 indicating undervaluation.
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both delivered strong quarters, but they tell very different dividend stories.
How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?
Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
3 Beaten-Down Healthcare Stocks to Buy in August
Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.
